Details of the Drug

General Information of Drug (ID: DMA5B1S)

Drug Name
KRN-330
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D07GNO

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cell surface A33 antigen (GPA33) TT96HUR GPA33_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cell surface A33 antigen (GPA33) DTT GPA33 1.62E-10 -1.19 -5.77
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.